

# CALL FOR ABSTRACTS

★ **Abstract Submission Deadline:** November 19, 2020

★ **Late-Breaking and Clinical Trials  
Abstract Submission Deadline:** January 11, 2021



Continuing Medical Education Activity -  
AMA PRA Category 1 Credits™ available

## AACR

American Association  
for Cancer Research®

## ANNUAL MEETING

### 2021

VIRTUAL ★ #AACR21

★ ★ ★ ★ ★ ★ ★

AACR.ORG ★ #AACR21



DISCOVERY  
SCIENCE  
DRIVING  
CLINICAL  
BREAKTHROUGHS

# AACR

American Association  
for Cancer Research®

## ANNUAL MEETING

### 2021

VIRTUAL ★ #AACR21



DISCOVERY  
SCIENCE  
DRIVING  
CLINICAL  
BREAKTHROUGHS

## AACR OFFICERS

### President

Antoni Ribas

### President-Elect

David A. Tuveson

### Treasurer

William N. Hait

### Immediate Past President

Elaine R. Mardis

### Chief Executive Officer

Margaret Foti

### Board of Directors

Adriana Albini

Scott A. Armstrong

René Bernards

Marcia R. Cruz-Correa

Keith T. Flaherty

Silvia Chiara Formenti

Elaine Fuchs

Roy S. Herbst

Carl H. June

Karen E. Knudsen

Edison T. Liu

Ira Mellman

Martine F. Roussel

Charles Swanton

Suzanne L. Topalian

## TABLE OF CONTENTS

2	Key Dates
3	Welcome
4	Scientific Program <ul style="list-style-type: none"><li>Plenary Sessions</li><li>Major Symposia</li><li>Advances Sessions</li><li>Forums</li><li>Educational Program</li></ul>
8	Policy Sessions
9	Spotlight on Clinical Trials
10	Professional Advancement Opportunities
11	Continuing Medical Education (CME)
12	Survivor and Patient Advocacy Program
13	Press Coverage and Social Media
14	Support for Attendance
16	Guidelines for Preparation and Submission of Abstracts
19	Abstract Categories
24	AACR Membership Opportunities
26	General Information
28	Annual Meeting Committees

### ABOUT THE COVER IMAGE:

©2020 American Association for Cancer Research


Inside of sphere (*clockwise*): AACR Virtual Special Conference:  
Epigenetics and Metabolism art; Glioblastoma (iStock); DNA sequencing (Getty)

Foreground of sphere (*clockwise*): 3D render of T cells attacking cancer cells (Getty);  
3D illustration of a method of DNA sequencing (Getty); Medical 3D illustration of a  
dividing cancer cell (Getty)

**AACR ANNUAL MEETING 2021**  
**KEY DATES**



September 30, 2020	Abstract Submission Opens
<b>October 13, 2020</b>	<b>Application Deadline: NextGen Stars</b>
November 12, 2020	Membership Application Deadline for Regular Abstract Sponsors and Scholar-in-Training Award Applicants
<b>November 19, 2020</b>	<b>Regular Abstract Submission Deadline (11:59 p.m. ET)</b>
<b>November 19, 2020</b>	<b>Application Deadlines:</b> <b>AACR Global Scholar-in-Training Awards</b> <b>AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards</b> <b>AACR Minority Scholar in Cancer Research Awards</b> <b>AACR Scholar-in-Training Awards</b> <b>AACR Women in Cancer Research Scholar Awards</b>
December 18, 2020	Late-Breaking and Clinical Trials Abstract Submission Opens
January 6, 2021	Online Itinerary Planner Available
January 7, 2021	Membership Application Deadline for Late-Breaking and Clinical Trials Abstract Sponsors
<b>January 11, 2021</b>	<b>Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)</b>
February 1, 2021	Regular Abstract Status Notifications Sent
<b>February 4, 2021</b>	<b>Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts</b>
February 10, 2021	Late-Breaking and Clinical Trials Abstract Notifications Sent
February 22, 2021	Regular Abstract Withdrawal Deadline
March 9, 2021	Late-Breaking and Clinical Trials Abstract Withdrawal Deadline



AACR ANNUAL MEETING 2021  
**WELCOME**



**Dear Members and Friends of the AACR,**

We are pleased to announce the Call for Abstracts for the 112th Annual Meeting of the American Association for Cancer Research (AACR). Reflecting the theme of this year's meeting, "Discovery Science Driving Clinical Breakthroughs," the scientific program will span the broad spectrum of cancer science and medicine from basic, translational, and clinical research including cancer health disparities; to early detection, interception, prevention, and population science; to regulatory science and policy.

The Opening Plenary Session will address the theme of the meeting and will include presentations on lineage tracing of tumor metastasis, tumor metabolism, genomic sequencing in diverse populations, immune surveillance, antitumor immune response, and clinical implications. New this year is the Discovery Science Plenary Session, which will focus on the mechanisms, impact, and exploitation of cancer chromosomal instability for potential therapeutic intervention. Also, a comprehensive educational program of more than 60 educational sessions and methods workshops, covering a wide array of disciplines and new technologies, is currently under development.

Major progress against cancer has been realized over the past few decades due to remarkable scientific advances and multidisciplinary collaborations, and during this year a record number of new cancer treatments were approved by the U.S. Food and Drug Administration. However, during the COVID-19 pandemic, many labs were forced to close, and clinics have needed to shift resources and refocus efforts to combat this enormous public health crisis. There is now much concern that the delays in cancer screening, diagnosis, and treatment because of the COVID-19 pandemic will have a significant negative impact on the pace of progress against cancer and on cancer patient outcomes. Now more than ever it is critically important to focus our collective efforts and resources on our mission to prevent and cure all cancers.

Despite these challenges, this has been a transformative year for the global cancer research community – one that has resulted in a new wave of scientific innovation that will be reflected in our Annual Meeting program. The year 2021 will be an exciting time for us to celebrate the 50th Anniversary of the signing of the National Cancer Act. The signing of this Act was a pivotal moment in history, as it has led to the formation of highly impactful comprehensive cancer centers in the U.S., the development of education and training programs for early-career laboratory and clinical investigators, increased funding for innovative cancer research, and many cancer breakthroughs that have saved millions of lives from the disease.

Proffered oral and poster presentations selected from submitted abstracts are a vital part of our Annual Meeting. For your interest, a new abstract category for research on COVID-19 and cancer has been added to our Call for Abstracts. We look forward to receiving your submissions and to providing an interactive venue for you to share your important work. Your participation in the 2021 Annual Meeting will not only be a welcome addition to the program, but it will also maximize collaborations, stimulate creative thinking about how to accelerate progress against cancer, and contribute greatly to the cause.

The regular abstract deadline is November 19, 2020. Our proffered program also features special oral presentation opportunities in several Clinical Trial Plenary Sessions for abstracts reporting on high-impact clinical trials. The deadline for late-breaking abstracts and clinical trial abstracts is January 11, 2021.

Please note that recently, the AACR Board of Directors approved an expansion of the abstract sponsorship privileges for certain AACR member types. We encourage AACR members to use their additional privileges to sponsor abstract submissions from their mentees and nonmember colleagues. Please view the details of these expanded privileges on page 18.


During these difficult times our heartfelt sympathies are extended to everyone who has been impacted by this global health crisis. It is our sincere hope that you join us virtually in 2021 to discuss your innovative work across the full spectrum of cancer research.

We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2021.


With best wishes and regards,

Antoni Ribas, MD, PhD, FAACR  
President, 2020-2021

Charles Swanton, FRCP, BSc, PhD, FAACR  
Chair, 2021 Program Committee



AACR ANNUAL MEETING 2021  
**SCIENTIFIC PROGRAM**



## WHY YOU SHOULD PARTICIPATE IN THE WORLD'S MOST IMPORTANT CANCER RESEARCH MEETING

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population science, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year's program, with the theme of "Discovery Science Driving Clinical Breakthroughs," will be a comprehensive, cutting-edge scientific event that you will not want to miss!

## PROGRAM IN PROGRESS

The Annual Meeting will include a comprehensive educational program comprised of Educational Sessions and Methods Workshops. In addition to the Opening Ceremony, Opening Plenary, and other thematic Plenary Sessions, a new and exciting Discovery Science Plenary Session will be open to all registrants. Abstracts submitted for the regular (November 19, 2020) or late-breaking and clinical trials (January 11, 2021) submission deadlines will be considered for short talks or ePoster presentations. The 2021 Program in Progress follows; additional exciting and timely invited sessions are being developed and will be posted at [AACR.org/AACR2021](https://AACR.org/AACR2021).

## PLENARY SESSIONS

### DISCOVERY SCIENCE PLENARY SESSION: MECHANISMS, IMPACT, AND EXPLOITATION OF CANCER CHROMOSOMAL INSTABILITY

David Pellman, Dana-Farber Cancer Institute, Boston, MA

Angelika Amon, Massachusetts Institute of Technology, Cambridge, MA

Stephen P. Jackson, University of Cambridge, Cambridge, United Kingdom

Karlene A. Cimprich, Stanford University, Stanford, CA

### OPENING PLENARY SESSION: DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS

**Chair: Charles Swanton**, The Francis Crick Institute, London, United Kingdom

Jonathan S. Weissman, Whitehead Institute, Cambridge, MA

Karen H. Vousden, The Francis Crick Institute, London, United Kingdom

Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA

Melissa B. Davis, Weill Cornell Medical College, New York, NY

Mark A. Dawson, Peter MacCallum Cancer Centre, Melbourne, Australia

Zhijian James Chen, UT Southwestern Medical School, Dallas, TX

### UNDERSTANDING THE MOLECULAR AND MICROENVIRONMENTAL DETERMINANTS OF CANCER

**Chair: Christina Curtis**, Stanford University, Stanford, CA

Garry P. Nolan, Stanford University School of Medicine, Stanford, CA

Serena Nik-Zainal, University of Cambridge, Cambridge, United Kingdom

Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Jérôme Galon, INSERM, Paris, France



**AACR ANNUAL MEETING 2021**  
**SCIENTIFIC PROGRAM**

**Plenary Sessions** (*cont'd*)

**CANCER BIOLOGY AND THE CHANGING THERAPEUTIC LANDSCAPE**

**Chair: Sheila A. Stewart**, Washington University, St. Louis, MO

Tony Hunter, Salk Institute, La Jolla, CA

William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA

Olufunmilayo I. Olopade, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL

Dennis J. Slamon, UCLA David Geffen School of Medicine, Los Angeles, CA

**LEVERAGING THE IMMUNE SYSTEM IN THE WAR ON CANCER**

**Chair: Nina Bhardwaj**, Icahn School of Medicine at Mount Sinai, New York, NY

Anjana Rao, La Jolla Institute for Immunology, La Jolla, CA

Sergio A. Quezada, University College London Cancer Institute, London, United Kingdom

Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

Ignacio Melero, University of Navarra, Pamplona, Spain

**MAJOR SYMPOSIA**

AACR-Bayard D. Clarkson Symposium on Stem Cells, Leukemia, and the Niche

Advances in Cancer Nanotechnology

Alternative DNA Repair Pathways and Their Drug Targets

Artificial Intelligence in Cancer Imaging

Artificial Intelligence/Machine Learning in Cancer Research and Care: Progress and Opportunities

Cancer Immunometabolism

Colorectal Cancer Interception: Immunologic and Pharmacologic Advances

COVID-19 and Cancer Research

Cytokine Receptors in Immuno-oncology: Discovery, Analysis, and Modulation

Deubiquitylating Enzymes as Targets for Cancer Therapy

Developing Rational Combinations of Targeted Drugs

Diet, Clock, and Cancer

Drugging KRAS

Engineering and Modulating Natural Killer Cells for Cancer Immunotherapy

Familial Predisposition: Precision Medicine and Targeted Therapy

From 'Omics Data to Prognostic and Predictive Biomarkers

Functional Precision Medicine in Cancer

Germline Influence on Immunotherapy Outcomes

Implications of Clonal Hematopoiesis in Human Health

Improving Therapy through Normalization of the Tumor Microenvironment

Matrix, Exosomes, and TME Cells in the Metastatic Niche

Mechanisms and Biomarkers of Response and Resistance to Immunotherapy

Metabolism and Chromatin Deregulation in Cancer and Cancer Heterogeneity

Modeling Metastatic Progression in the Mouse

Molecular Imaging

Neoadjuvant Immunotherapy for Melanoma and Other Cancers

New Approaches to Chimeric Antigen Receptor Engineering

New Combinations of Targeted Therapies and Immunotherapies

Next Frontiers in Adjuvant Therapy

Next-Generation Epigenetic Drugs

Options and Opportunities for Treating Metastasis

Paracrine Signaling in Cancer

Phase Separation, Transcription, and Cancer

Progress from Personalized Cancer Vaccine Trials

T Cells in Cancer

The Cancer Dependency Map

The Clinical Proteomic Tumor Analysis Consortium: Building a Proteogenomic Atlas of Cancer

The Microbiome in Cancer Therapy: Hype or Hope?

The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response



**AACR ANNUAL MEETING 2021**  
**SCIENTIFIC PROGRAM**

**Major Symposia** *(cont'd)*

Toward Engineering of Neoantigen-Specific T-Cell Therapies

Tumor Cell Plasticity and Resistance to Cancer Therapies

Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets

When Is Transforming Growth Factor Beta Targetable?

AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer

AACR-CSCO Joint Symposium: Single-Cell Analysis—Changing the Landscape of Cancer Research

AACR-JCA Joint Session: Tracking Tumor Evolutionary Dynamics: From Initiation through Metastasis

AACR-ONS Special Session: Symptom Science

**ADVANCES IN DIAGNOSTICS AND THERAPEUTICS**

Advances in Drug Delivery

Computational Methods for Immunogenomics and Precision Oncology

Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions

DNA Damage Response (DDR) Treatment: Evolving Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting Therapies

Hybrid Technologies for Cancer Imaging, Theranostics, and Image-Guided Interventions

Management of Toxicity of Immune Cell Therapy

Noninvasive Monitoring of Minimal Residual Disease with Liquid Biopsies: Toward Real-Time Treatment Decision-Making

Proton Therapy and FLASH Irradiation

Targeting Transcriptional Cyclin-Dependent Kinases in Cancer

Translational Canine Models Advancing Immunotherapy and Immunogenomics

Understanding and Overcoming Resistance to Third Generation EGFR and ALK Inhibitors

**ADVANCES IN ORGAN SITE RESEARCH**

Advances in Endometrial Cancer

Advances in Sarcoma Therapy

Developing More Effective Treatments for Triple-Negative Breast Cancer

Diffuse Large B-Cell Lymphoma

Emerging Concepts in Liver Cancer Research

Next-Generation Treatments for Melanoma: Building on Success

Pathways to Early Detection of Pancreatic Cancer

Solid Tumor Brain Metastasis

Targeting Signaling Pathways in Colorectal Cancer

Therapeutic Advances in Biliary Tract Cancers

Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer

**ADVANCES IN PREVENTION, EARLY DETECTION, AND INTERCEPTION**

Connecting the Tumor Microenvironment with the Macroenvironment in Cancer Cachexia

Interception of Preneoplasia

Molecular Targets of Precision Prevention and Interception

Panel on Rural Cancer Control

Radiation-Induced Cancers and Cancer Survivorship

**ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES**

Carcinogenic Exposures and Global Cancer Prevention

Pan-Cancer Distinctions in Tumor Biology across Ethnicity and Genetic Ancestry

Precision Medicine in Underserved Populations

## FORUMS

Are Antitumor T Cells Exhausted or Dysfunctional?  
Does It Matter?

Are There Cancer Stem Cells?

Biostatistics Debate: Should Science Be Guided by  
P-Values?

Cancer Cell Dormancy: The Current Paradigm and the  
Challenges Ahead to Develop New Therapies

CAR T-Cell Therapy or T-Cell Engager?

Data Science and Machine Learning: Will They  
Revolutionize Cancer Cure and Research?

Embracing Entrepreneurship in Cancer Research

Microbiome Pandemonium: Checkpoints and  
the Microbiome

Patient-Derived Models for Cancer

The Myths and Realities of the Abscopal Effects

What Is the Role for Oncolytic Viruses in Cancer  
Treatment?

## EDUCATIONAL PROGRAM: EDUCATIONAL SESSIONS AND METHODS WORKSHOPS

The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base. The Educational Program consists of more than 65 unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program will be available at **AACR.org/AACR2021**.

- ★ Tumor Immunology and Immunotherapy for Nonimmunologists. Annually, this two-part series combines a comprehensive review of a hot topic in the field with a networking session that enables attendees to participate in group discussions with leading experts in the field.
- ★ Chemistry to the Clinic. This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, and drug modalities.
- ★ Clinical Trial Design. Over the course of three consecutive sessions, this Methods Workshop will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at  
**AACR.org/AACR2021**.

## AACR ANNUAL MEETING 2021

# POLICY SESSIONS



Decisions made by policymakers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policymakers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The **Science and Health Policy Track** includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases. Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The **Regulatory Science and Policy Track** includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The **Science of Survivorship Track** includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.



## SUBMIT YOUR CLINICAL TRIALS ABSTRACTS TO THE AACR ANNUAL MEETING 2021

Become a part of our growing clinical research program at the Annual Meeting and help us showcase how discovery science continues to transform the lives of cancer patients.

### WHY YOU SHOULD SUBMIT

- ★ Numerous and unique oral presentation opportunities
  - Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  - Three Clinical Trials Minisymposia
- ★ Poster presentations (enhanced e-Posters with opportunities for engagement)
- ★ Opportunities for extensive national media coverage through the AACR press program
- ★ Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
  - Indicate your intention to submit a manuscript during the abstract submission process.
  - Contact [pubs@aacr.org](mailto:pubs@aacr.org) with any questions.
- ★ No restrictions on presenters if the presentation is CME-compliant

### WHAT TO SUBMIT

- ★ Any phase (I, II, III, or any combination) abstract from national or international clinical trials
- ★ Promising ongoing trials, or unique trial designs that have not yet yielded results, to the Clinical Trials in Progress category (CT08)
- ★ Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the review committee).
- ★ COVID-19 and cancer clinical trials to the COVID-19 and Cancer (COVID06) or Clinical Trials (CT07) categories.
- ★ See pages 21-22 for clinical trials (CT) abstract categories and visit [AACR.org/AACR2021](https://aacr.org/AACR2021) for submission guidelines.

### WHEN TO SUBMIT

- ★ Submit your completed or placeholder abstract(s) by the January 11, 2021 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 19, 2020 deadline.
- ★ Final results and conclusions for placeholder abstracts are due by February 4, 2021.

## AACR VIRTUAL ANNUAL MEETINGS I AND II 2020

30

TRIALS IN CLINICAL  
PLENARY SESSIONS

104

TRIALS IN  
POSTER SESSIONS

50

TRIALS IN PROGRESS  
IN POSTER SESSIONS

# PROFESSIONAL ADVANCEMENT OPPORTUNITIES



In support of its mission to promote the education and training of cancer scientists and clinicians and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to enhance and advance their careers. For more information about any of the professional development opportunities that follow, visit [AACR.org/AACR2021](https://AACR.org/AACR2021) and click on the “Professional Development Opportunities” tab.

## NEXTGEN STARS

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2021. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak.

The deadline to submit applications was **12:00 p.m. U.S. ET, October 13, 2020**. Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2021 will receive travel support and complimentary registration for the meeting. Details can be found at [AACR.org/AACR2021](https://AACR.org/AACR2021) under the “NextGen Stars” tab.

## PROFESSIONAL ADVANCEMENT SESSIONS

### Exclusive Member Benefit

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience, representing the AACR’s dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. Each year, several interactive and engaging professional development and career advancement opportunities are organized to provide important skills to investigators at all levels, from students to senior faculty.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as a Student Member (high school students and undergraduates) or Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research). If you are not an AACR member, you are strongly encouraged to join and take advantage of being able to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, and reduced member registration rates for the Annual Meeting 2021. Visit [AACR.org/Membership](https://AACR.org/Membership) to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2021 will be announced in the fall. Visit [AACR.org/PAS](https://AACR.org/PAS) for session updates, including opportunities for physician-scientists and early-career and early-stage investigators.

## CONTINUING MEDICAL EDUCATION (CME)



The AACR's Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2021 will be a Continuing Medical Education Activity and *AMA PRA Category 1 Credits™* will be available. This is a great opportunity to complete your required credit hours.



## MEET YOUR MOC POINT REQUIREMENTS

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2021. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine's (ABIM) Maintenance of Certification program.

## SURVIVOR AND PATIENT ADVOCACY PROGRAM



### AACR'S COMMITMENT TO SURVIVORS AND PATIENT ADVOCATES

The voices of patients with cancer have never been more important than in today's environment, especially as patients are partnering with researchers by selflessly donating tissue and personal data to advance progress. Additionally, patient advocates play a crucial role in educating the public about new research discoveries, serving on committees and panels to inform cancer research and regulatory policies, increasing awareness among legislators, and raising precious funds for cancer research.

The AACR recognizes and celebrates the contributions of survivors and patient advocates to cancer research and policy and welcomes their attendance and participation at the AACR Annual Meeting.

Discounted registration rates are available for patient advocates.

### AACR SCIENTIST↔SURVIVOR PROGRAM

A special advocacy program that the AACR hosts each year is the AACR Scientist↔Survivor Program (SSP), which is now in its 23rd year. Led admirably since its inception by Anna D. Barker, PhD, of the Lawrence J. Ellison Institute for Transformative Medicine of USC, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process and occurs twice each year, with the larger program being held in conjunction with the AACR Annual Meeting.

This unique program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, physicians, health care professionals, and other advocates.

Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures in lay terms; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year's SSP, please visit [AACR.org/SSP2021](https://aacr.org/SSP2021) or contact us at [advocacy@aacr.org](mailto:advocacy@aacr.org).

Patient advocates can also engage with the AACR in many ways throughout the year, including through AACR's magazine *Cancer Today*, the AACR Foundation, the annual *AACR Cancer Progress Report*, and by participating in advocacy days on Capitol Hill.



## ATTRACTING JOURNALISTS WORLDWIDE, GENERATING MAJOR NEWS COVERAGE

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Virtual Annual Meetings I and II, held in April and June 2020, attracted a total of 174 registered reporters. The two meetings showcased innovative clinical, translational, and basic research and generated nearly 2,500 media clips in leading consumer and trade outlets including The Associated Press, *The New York Times*, *The Washington Post*, Reuters, STAT, and *Science*, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2021 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at [julia.gunther@aacr.org](mailto:julia.gunther@aacr.org) or Rick Buck at [rick.buck@aacr.org](mailto:rick.buck@aacr.org).

## UTILIZING SOCIAL MEDIA TO AMPLIFY THE CONVERSATION

The AACR Virtual Annual Meetings I and II 2020 also generated significant social media activity in the cancer research community. Social media highlights included:

### AACR Virtual Annual Meeting I 2020:

2,758

PEOPLE JOINING THE  
CONVERSATION ON TWITTER

9,003

TOTAL TWEETS USING  
THE #AACR20 HASHTAG

45,427,000

TOTAL IMPRESSIONS

### AACR Virtual Annual Meeting II 2020:

2,307

PEOPLE JOINING THE  
CONVERSATION ON TWITTER

7,065

TOTAL TWEETS USING  
THE #AACR20 HASHTAG

42,426,000

TOTAL IMPRESSIONS



Through the generosity of its loyal supporters and grants from the National Cancer Institute (NCI), the AACR is pleased to provide support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, can be found by visiting [AACR.org/AACR2021](https://AACR.org/AACR2021) and clicking on the “Financial Support for Attendance” link.

## AACR SCHOLAR-IN-TRAINING AWARDS

### Exclusive Member Benefit

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious abstracts at the AACR Annual Meeting. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 12, 2020**. The AACR Membership Application Form is available on the AACR website at [AACR.org/Membership](https://AACR.org/Membership). To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit [AACR.org/SITA](https://AACR.org/SITA). Application deadline: **November 19, 2020**.

## AACR GLOBAL SCHOLAR-IN-TRAINING AWARDS

Global Scholar-in-Training Awards (GSITA) are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2021 and then complete a separate GSITA application. Applicants must be members of the AACR in good standing (membership current through 2020). Nonmembers who wish to apply should submit a Membership Application Form by **November 12, 2020** before submitting their GSITA application. For additional details and a list of eligible developing countries, visit [AACR.org/GSITA](https://AACR.org/GSITA). Application deadline: **November 19, 2020**.

## AACR-MINORITIES IN CANCER RESEARCH (MICR)-SPONSORED AWARDS

Minorities in Cancer Research (MICR)—a membership group within the AACR—is working to increase the number, participation, visibility, and recognition of minority scientists in cancer research. The AACR Minority and Minority-Serving Institution Faculty Scholar Awards and Minority Scholar Awards are two of several programs sponsored by MICR in support of its mission. These awards are generously supported by the NCI Center to Reduce Cancer Health Disparities. To learn more, please visit [AACR.org/MICR](https://AACR.org/MICR) or send an email to [micr@aacr.org](mailto:micr@aacr.org).

**AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards:** Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage



# GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS



**AACR Abstract Submission System.** Authors must submit abstracts for presentation at the Annual Meeting 2021 using the AACR Abstract Submission System, which is available at **AACR.org/AACR2021**. You can create, modify, and submit abstracts until the November 19, 2020, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

**Note for 2021:** Submit your abstract detailing how you use AACR Project GENIE data by the November 19, 2020, deadline for an opportunity to be featured in a special session during the Annual Meeting 2021. Simply include GENIE as a keyword during the submission process.

The Abstract Submission System has been optimized for the current versions of most browsers:

- ★ **Google Chrome:** Version 23.0 or higher
- ★ **Internet Explorer:** Version 9.0 or higher
- ★ **Mozilla Firefox:** Version 27.0 or higher
- ★ **Safari:** Version 7.1 or higher
- ★ **Microsoft Edge:** Version 79.0 or higher

Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or [aacr@support.ctimeetingtech.com](mailto:aacr@support.ctimeetingtech.com).

**Responsibilities of Authors.** By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

★ **Support for Abstract/Verification of Authorship.**

All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via email.

★ **Sponsorship of Abstracts.** The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 18 for Abstract Sponsorship Regulations.

★ **Transfer of Copyright.** On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

★ **Presentation of Abstracts.** The submitting author for each abstract must designate a presenter who agrees to register for the meeting and participate in the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot participate in the meeting, the authors are expected to designate a replacement. If no presenter is available, or if the presenter does not register for the meeting, the abstract will be withdrawn.

★ **Confirmation of No Prior Publication/Presentation.**

Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2021.

Exception: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 11, 2021, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented.

**Content of Abstracts.** Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).

**Abstract Control Number.** An Abstract Control Number (e.g., 21-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

**Financial Relationships of Coauthors.** Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships

## AACR ANNUAL MEETING 2021 GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS *(cont'd)*

of each of your coauthors. For more information on financial relationships, visit [AACR.org/CME](https://www.aacr.org/CME).

**Sponsor Permission and Information.** Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 18.

**Length of Abstracts.** The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

**Abstract Category, Subcategory, and Subclassification.** You must select a category, subcategory, and subclassification for your abstract. See pages 19-23 for details.

**Disclosure of Chemical Structures.** At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

**Submission Fee.** Each abstract submitted must be accompanied by a **\$65 abstract submission fee**. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

**Abstract Deadline.** The deadline for abstract submissions is **11:59 p.m. U.S. ET, Thursday, November 19, 2020**. Abstracts submitted after the deadline will not be considered by the Program Committee. **No significant changes may be made to abstracts after the November 19, 2020, deadline.**

**Note:** Submitting an abstract for presentation at the AACR Annual Meeting 2021 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at [AACR.org/AACR2021](https://www.aacr.org/AACR2021).

**Late-Breaking Abstract Deadline.** The deadline for late-breaking abstracts is **11:59 p.m. U.S. ET, Monday, January 11, 2021**. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

**Clinical Trials Abstract Deadline.** All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. The deadline for clinical trials abstracts is **11:59 p.m. U.S. ET, Monday, January 11, 2021**. Final data for placeholder abstracts are due **Thursday, February 4, 2021** (see page 9). Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

**Publication Opportunity.** For consideration of simultaneous publication in an AACR journal, please contact the AACR Publishing Division at [pubs@aacr.org](mailto:pubs@aacr.org).

**Presentation of Proffered Papers at the AACR Annual Meeting.** Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must participate in the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. Presentation formats for 2021 include ePosters with enhanced engagement and networking opportunities and short talks in minisymposia. If, due to unforeseen circumstances, the designated presenter is unavailable to register for the meeting and participate in the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to register for the meeting and present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or [abstractchanges@aacr.org](mailto:abstractchanges@aacr.org). Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

- ★ The withdrawal of the abstract from the session
- ★ The removal of the abstract from the online *Proceedings*
- ★ The loss of future sponsorship privileges for the sponsor of the abstract
- ★ The loss of future abstract submission/authorship privileges for the presenter of the abstract

**Deadline for Withdrawal of Abstracts.** Requests to withdraw regular abstracts will be accepted through **Monday, February 22, 2021**. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through **Tuesday, March 9, 2021**. Withdrawal requests must be sent by email to [abstractchanges@aacr.org](mailto:abstractchanges@aacr.org). Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

## ABSTRACT SPONSORSHIP REGULATIONS

### Expanded Abstract Sponsorship Privileges for AACR Members

Expanded abstract sponsorship privileges for selected AACR member types are available for the AACR Annual Meeting 2021, as outlined below:

- ★ **Active, Honorary, and Emeritus Members** may now sponsor an **unlimited number of abstracts** for presentation at the meeting. (As always, members must verify the content, authenticity, and quality of the abstracts they agree to sponsor.)
- ★ **Affiliate Members** are still permitted to sponsor one abstract for each deadline provided that they are the presenter of the abstract. However, Affiliate Members are **no longer required to provide an endorser** for their abstract.

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 19 regular abstract deadline, member dues must be paid in full through 2020. To be in good standing for the January 11 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2021. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.


1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing. (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.
3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts while still retaining their right to sponsor an unlimited number of abstracts.
4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are no longer required to provide an endorser.)
5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.
6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

**COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS.** Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

## MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract for Annual Meeting 2021 must submit an application for membership no later than **November 12, 2020**. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than **January 7, 2021**. Membership questions may be directed to [membership@aacr.org](mailto:membership@aacr.org).



The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. **The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).**

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.

## MCB Molecular and Cellular Biology, Genetics

### MCB01 Cell Growth Signaling Pathways

Cell signaling  
Cell-cell interactions  
Growth factors  
GTPases, their regulators, and effectors  
Kinases and phosphatases  
Receptors  
Tumor-stromal cell interactions  
Ubiquitin and ubiquitin-like proteins  
Other

### MCB02 Cell Death

Apoptosis  
Autophagy  
Bcl-2 family proteins  
Caspases  
Effectors of apoptosis  
Inhibitor of apoptosis (IAP) family proteins  
Necrosis and necroptosis  
Transcriptional control of apoptosis  
Other

### MCB03 Oncogenes and Tumor Suppressor Genes

Cytoplasmic signal transducers  
Genotype/phenotype correlations  
Nuclear oncoproteins and tumor suppressor genes  
Oncogene growth factors and their receptors  
Tumor suppressor genes  
Other

### MCB04 Gene Regulation and Transcription Factors

Chromatin structure and function  
Gene expression  
Mechanisms of transcription  
Oncogenic transcription factors  
Posttranscriptional and translational control  
Promoters and enhancers of transcription  
Protein-protein interactions in transcription factor function

Regulation of transcription factor function  
Transcriptional control of cell differentiation  
Other

### MCB05 Epigenetics

Chromatin structure and function  
DNA methylation  
Epigenetic changes as molecular markers of cancer  
Epigenomics  
Gene silencing  
Histone modification  
Other

### MCB06 Cell Cycle

CDKs and CDK inhibitors  
Cell cycle checkpoints  
Control of cell cycle progression  
Mitosis  
Telomeres and telomerase  
Other

### MCB07 DNA Damage and Repair

Chromosomal structural alterations/translocations  
Genomic instability  
Homologous recombination  
Mechanisms of genomic alterations  
Radiation-induced DNA damage  
Other

### MCB08 Metabolism and Cancer

Metabolic pathways  
Metabolomics  
Mitochondrial function  
Signaling pathways that regulate metabolism  
Warburg effect  
Other

### MCB09 Genomics

(See also BSB01: Bioinformatics and Computational Biology)  
Functional genomics  
Genomic profiling of tumors  
High-throughput sequencing

Large-scale approaches to cancer gene discovery  
Microarrays  
Other

### MCB10 microRNAs and Other Noncoding RNAs

Epigenetic control of miRNA expression  
miRNA profiling in cancer  
miRNA regulation of cancer biology  
miRNA-based diagnostics  
miRNA-based therapeutics  
miRNAs as tumor suppressors/oncogenes  
Noncoding RNAs  
Other

### MCB11 Cellular Stress Responses

Hypoxia  
Oxidative stress  
Senescence  
Unfolded protein response  
Other

## BSB Bioinformatics, Convergence Science, and Systems Biology

### BSB01 Bioinformatics and Computational Biology

(See also MCB09: Genomics)  
Analytic pipeline optimization  
Application of bioinformatics to cancer biology  
Database resources  
Molecular modeling  
New algorithms  
New software for data analysis  
Sequence analysis  
Statistical methods  
Other

**BSB02 Convergence Science and Systems Biology**

Artificial intelligence and machine learning  
Integrative cancer biology  
Mathematical modeling  
Network biology  
Physical sciences and engineering  
Systems engineering  
Other

**TB Tumor Biology**

**TB01 Nonclinical Models of Cancer**

3-D and tissue recombinant models  
Developmental phenotypes of cancer genes  
Human-in-mouse models of human cancer  
Model organisms in drug discovery  
Mouse models of human cancer  
Noninvasive imaging in animal models  
Organoids  
Patient-derived xenograft models  
Zebrafish models of cancer  
Other animal and cell models of cancer  
Other

**TB02 Stem Cell Biology**

Adult stem cells  
Cancer stem cells  
Developmental pathways in cancer  
Embryonic stem cells  
Stem cell markers  
Stem cells and regenerative medicine in oncology  
Other

**TB03 Tumor Adhesion**

Cell adhesion and extracellular matrix  
Cell-cell adhesion  
Drug resistance  
Other

**TB04 Invasion and Metastasis**

Actin cytoskeleton  
Biomarkers of metastasis  
Epithelial/mesenchymal transition (EMT and MET)  
Expression profiling of tumor progression and metastasis  
Genes that regulate migration and invasion  
Imaging of tumor progression and metastasis  
Invasion and migration  
Metastasis suppressor genes  
Metastasis-promoting genes  
Premetastatic niche  
Therapeutic metastasis prevention  
Other

**TB05 Angiogenesis**

Angiogenesis and angiogenesis inhibitors  
Host-tumor interactions  
Molecular mechanisms of angiogenesis  
Novel pro- and antiangiogenic factors  
Tumor microcirculation and the microenvironment  
Other

**TB06 Tumor Microenvironment**

Chemokines in the microenvironment  
Drug targets in the microenvironment  
Extracellular matrix and integrins  
Gene expression in the microenvironment  
Immune cells in the tumor microenvironment  
Immunity and the microenvironment  
Inflammatory cells as regulators of tumor growth  
Microbiome  
Organ-specific microenvironments  
Proteases and inhibitors in the microenvironment  
Tumor dormancy  
Tumor/stromal interactions  
Tumor-immune system interactions  
Other

**TB07 In Vivo Imaging**

(See also CL01: Translational Research – Molecular Biology in the Clinic)  
Advanced nanotechnology and imaging  
Application of imaging technology to the clinic  
Imaging in animal models  
Imaging of molecular and cellular events in the tumor microenvironment  
Imaging of molecular and cellular events in tumors and tumor cells  
Imaging the immune response  
Imaging tumor metabolism  
New targets for imaging  
Other

**TB08 Pediatric Cancer - Basic Science**

(See also CL02: Pediatric Cancer – Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)  
Developmental origins and drivers of pediatric cancer  
Pediatric cancer epigenomics and genomics  
Pediatric cancer models  
Pediatric cancer tumor microenvironment and tumor heterogeneity  
Other

**TB09 Radiation Science**

(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics)  
Modulators of radiation response  
Photobiology/photodynamic therapy  
Radiation dose fractionation  
Radiation-activated signaling pathways  
Radiation-induced gene expression  
Radiation-induced resistance  
Radiobiology research  
Radioprotectors and radiosensitizers  
Other

**TB10 Tumor Evolution and Heterogeneity**

Causes and consequences of tumor heterogeneity  
Complex adaptive systems  
Methods to measure tumor evolution and heterogeneity  
Other

**TB11 Carcinogenesis**

Carcinogenesis: Chemical, environmental, and molecular  
Mutagenesis  
Tumor initiation and promotion  
Viral-induced carcinogenesis  
Other

**CH Cancer Chemistry**

**CH01 Drug Discovery, Design, and Delivery**

Basic and applied nanotechnology and therapeutics  
Cheminformatics, in silico screening, and computational methods  
Drug delivery  
Drug design  
High-throughput screening (assays and libraries)  
Lead identification  
Lead optimization  
Nanotechnology drug delivery  
Natural products  
Synthesis, metabolism, and disposition  
Other

**CH02 Structural and Chemical Biology**

Chemical genetics and genomics  
Nanotechnology in chemical biology  
Small molecule, protein, and nucleic acid interactions  
Target identification, small molecule probes, and libraries  
X-ray and NMR structures  
Other

**CH03 Proteomics and Mass Spectrometry**

Biological mass spectrometry and systems biology  
Proteomics and biomarker discovery  
Proteomics and signaling networks  
Other

**ET Experimental and Molecular Therapeutics**

**ET01 Drug Discovery**

Antibody technologies  
Biochemical modulators of the therapeutic index  
Combination chemotherapies  
Differentiation therapy  
New targets  
Novel assay technology  
Novel drug delivery systems  
Targeting the tumor microenvironment in drug development  
Other

**ET02 Mechanisms of Drug Action**

Cell cycle mechanisms of anticancer drug action  
Cellular responses to anticancer drugs  
Interactions of new agents with radiation  
Role of the microenvironment in therapeutic response  
Other

**ET03 Drug Resistance**

Drug resistance in molecular targeted therapies  
Drug transport and metabolism  
Novel mechanisms  
Regulation of gene expression in drug resistance  
Reversal of drug resistance  
Other

**ET04 Molecular Targets**

Cell death pathways and treatment  
Identification of molecular targets  
Modulation of DNA repair  
Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes  
New nonclinical models for targets  
Other

**ET05 Pharmacology, Pharmacogenetics, and Pharmacogenomics**

(See also CT01: Phase I Adult Clinical Trials)  
Cellular pharmacology  
Molecular pharmacology  
Pharmacogenetics and therapeutic response  
Pharmacogenomics  
Pharmacokinetics and pharmacodynamics  
Preclinical toxicology  
Other

**ET06 Small Molecule Therapeutic Agents**

DNA-reactive agents  
Epigenetic targets  
HDAC and methyltransferase inhibitors  
Novel antitumor agents  
Novel targets and pathways  
PI3K/AKT inhibitors  
Proteasome inhibitors

Topoisomerases  
Tubulin agents  
Tyrosine kinase and phosphatase inhibitors  
Other

**ET07 Biological Therapeutic Agents**

(See also CL06: Immuno-oncology; IM02: Immunotherapy, Preclinical and Clinical)  
Antireceptors  
Apoptosis: Therapeutic manipulation  
Growth factor receptors and other surface antigens as targets for therapy  
Oncogenes, tumor suppressor genes, and gene products as targets for therapy  
Protein kinases and phosphatases as targets for therapy  
Role of microenvironment in therapeutic response  
Other

**ET08 Gene and Vector-Based Therapy**

Antisense molecules  
Gene therapy and radiation studies  
Immune modulators  
Vector systems and targeting strategies  
Other

**ET09 Preclinical Radiotherapeutics**

(See also TB09: Radiation Science; CL07: Radiation Oncology)  
Modification of radiosensitivity  
Molecular targets of radiation response  
Normal tissue/cellular stress responses to radiation  
Radioprotectors and radiosensitizers  
Radiotherapeutic combinations  
Other

**IM Immunology**

**IM01 Tumor Immunobiology**

Adaptive immunity in tumors  
Epigenetic regulation of tumor immunity  
Inflammation and cancer: Metastasis  
Inflammation and cancer: Tumor initiation and progression  
Innate immunity to tumors  
Microbiome, inflammation, and cancer  
Novel animal models  
Oncogenic pathway-mediated regulation of inflammation and tumor immunity  
Tumor antigenicity/processing and presentation  
Tumor-induced immune suppression: Extrinsic factors  
Tumor-induced immune suppression: Intrinsic factors  
Other

**IM02 Immunotherapy, Preclinical and Clinical**

(See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents)  
Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other therapies including chemotherapy  
Immune mechanisms invoked by radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered antibodies  
Vaccines (oncolytic and prophylactic)  
Other

**CT Clinical Trials**

**(Including Combination and Immunotherapy Trials)**

All clinical trials should be submitted by the January 11, 2021 clinical trials abstract deadline.

**CT01 Phase I Adult Clinical Trials**

(See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

**CT02 Phase II Adult Clinical Trials**

**CT03 Phase III Adult Clinical Trials**

**CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer**

(See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)

**CT05 Phase I, II, or III Clinical Trials in the Elderly**

**CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations**

**CT07 Clinical Trials for COVID-19**  
[See also COVID06: Clinical Trials  
(Phase I–Phase IV and Trials in  
Progress)]

Phase I  
Phase II  
Phase III  
Phase IV, observational, and expanded access  
Clinical trials in progress

**CT08 Clinical Trials in Progress**  
Phase I clinical trials in progress  
Phase II clinical trials in progress  
Phase III clinical trials in progress

**CL Clinical Research**  
[not including clinical trials;  
see also the Clinical Trials (CT)  
categories]

**CL01 Translational Research – Molecular  
Biology in the Clinic**  
(See also: TB07: In Vivo Imaging)

Clinical imaging  
Cytogenetics and clinical molecular genetics  
Epigenetic therapy  
Functional and molecular imaging  
Laboratory correlates for targeted agents  
Molecular classification of tumors  
Radiomics  
Tumor staging: Correlation of clinical and  
molecular markers  
Other

**CL02 Pediatric Cancer –  
Clinical Investigations**  
(See also CT04: Phase I, II, or III  
Clinical Trials in Pediatric Cancer;  
TB08: Pediatric Cancer – Basic  
Science)

Adolescent and young adult oncology  
Childhood cancer drug development  
Immunotherapeutic approaches to pediatric  
cancer  
Pediatric cancer predisposition and surveillance  
Survivorship, late effects, and secondary  
cancers  
Therapeutic dosing, resistance, and  
combination therapy approaches in  
pediatric oncology  
Translational pediatric cancer research  
Other

**CL03 Clinical Research in the Elderly**  
Aging, immunity, and cancer  
Other

**CL04 Clinical Research in Racial and  
Ethnic Minorities and Other  
Underserved Populations**

Biobanking/biospecimen collection  
Clinical trial design  
Community engaged research/community-  
based participatory research  
Patient accrual and retention  
Patient navigation  
Other

**CL05 Biostatistics in Clinical Trials**  
Design and analysis of clinical trials  
New study designs: Theory, methodology, and  
modeling  
Statistical modeling for cancer studies  
Other

**CL06 Immuno-oncology**  
(See also ET07: Biological  
Therapeutic Agents; IM02:  
Immunotherapy, Preclinical and  
Clinical)

Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other  
therapies including chemotherapy  
Immune mechanisms invoked by  
radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered  
antibodies  
Vaccines (oncolytic and prophylactic)  
Other

**CL07 Radiation Oncology**  
(See also TB09: Radiation Science;  
ET09: Preclinical Radiotherapeutics)

Clinical radiotherapeutic studies  
Interventional radiology  
Modification of radiosensitivity  
Radiation-immunotherapy and other  
radiotherapeutic combinations  
Radiation-induced late effects/secondary  
cancers  
Radiation-induced resistance  
Other

**CL08 Surgical Oncology (including  
Prophylactic Surgery)**

Surgical oncology

**CL09 Clinical Endocrinology**  
(See also EN01: Molecular,  
Preclinical, and Clinical  
Endocrinology)

Endocrine-related cancers  
Hormone receptors and diagnosis/prognosis  
Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors  
Neuroendocrine and other endocrine factors  
Nuclear receptors: Structure and function  
Preclinical studies of endocrine-related cancers  
Receptors and signal transduction  
Steroid hormone receptors  
Other

**CL10 Survivorship Research and  
Supportive Care**

Biology of cell and tissue damage  
Comparative effectiveness research and  
cost-effective studies  
Late effects and second cancers  
Psycho-oncology  
Supportive care, palliation, and pain  
management  
Translational survivorship research  
Other

**CL11 Biomarkers**  
Biomarkers predictive of therapeutic benefit  
Diagnostic biomarkers  
Early detection biomarkers  
Liquid biopsies: Circulating DNA  
Liquid biopsies: Circulating tumor cells  
Metastasis biomarkers  
Prognostic biomarkers  
Other

**CL12 Clinical Outcomes Research**  
Clinical outcomes research

**EN Endocrinology**

**EN01 Molecular, Preclinical, and  
Clinical Endocrinology**  
(See also CL09: Clinical  
Endocrinology)

Endocrine-related cancers  
Growth factors, receptors, and signal  
transduction  
Hormone receptors and diagnosis/prognosis  
Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors  
Neuroendocrine and other endocrine factors  
Nuclear receptors: Structure and function  
Preclinical studies of endocrine-related cancers  
Receptors and signal transduction  
Steroid hormone receptors  
Other

**EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)**

**EP01 Epidemiology**

Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects  
Biomarkers of prognosis  
Cancer health disparities research  
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends  
Diet, alcohol, tobacco use, and other lifestyle risk factors  
Environmental and occupational risk factors  
Familial and hereditary cancers  
Functional studies of genetic variants  
Gene-gene and gene-environment interactions  
Genome-wide association studies (GWAS)/ post-GWAS  
Health services and comparative effectiveness research  
Infection and immune factors  
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)  
Pathway and candidate gene studies of risk or prognosis  
Pharmacoevidence  
Preneoplastic and tumor markers  
Primary and secondary intervention studies  
Risk prediction models for incidence, prognosis, and/or mortality  
Screening and early detection  
Statistical and epidemiological methodology  
Survivorship research  
Other

**PR Prevention, Early Detection, and Interception**

**PR01 Preclinical Prevention, Early Detection, and Interception**

Animal models in prevention  
Biological and biochemical mechanisms in prevention  
Biomarkers and intervention studies  
Cellular models  
Chemoprevention studies  
Diet, nutrition, and cancer  
Microbiome and prevention  
Molecular markers in prevention research  
Molecular targets for prevention  
New agent development  
Screening and early detection  
Other

**PR02 Clinical Prevention, Early Detection, and Interception**

Application of molecular pathology in clinical prevention  
Biomarkers and intervention studies  
Cancer health disparities research  
Cancer surveillance and screening studies  
Chemoprevention clinical trials

Genetic markers as surrogate endpoints in prevention trials  
Genomics and proteomics in cancer risk and response assessment  
Infections and viral-related cancers  
Microbiome and prevention  
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)  
Prevention of second cancers  
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials  
Screening and early detection  
Other

**PR03 Implementation Science**

Behavioral science and prevention  
Cancer communication and decision-making  
Cancer health disparities research  
Genetic testing and counseling  
Health policy and outcomes  
Obesity, diet, physical activity, and energy balance  
Quality of life/late effects/survivorship  
Other

**COVID COVID-19 and Cancer**

**COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer**

Biomarkers/predictors of COVID-19 and cancer  
Host genomics and genetics  
Immunobiology  
Pathophysiology  
Viral evolution  
Other

**COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation**

**COVID03 Cancer Drug Repurposing to Treat COVID-19**

**COVID04 COVID-19 Vaccine Development**

**COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)**

**COVID06 Clinical Trials**

[See also CT07: Clinical Trials for COVID-19 (Phase I-Phase IV and Trials in Progress)]

Phase I  
Phase II  
Phase III  
Phase IV, observational, and expanded access  
Clinical trials in progress

**COVID07 Continuity of Cancer Care**

Long-term cancer outcomes  
Novel health care strategies (including telehealth and digital health)

Palliative care  
Patient management  
Treatment modifications  
Other

**COVID08 Effects of COVID-19 on Cancer Survivorship**

Long-term health-related quality of life issues  
Psychosocial impact on patients and health care workers  
Other

**COVID09 Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19**

**COVID10 Cancer Prevention and Early Detection during the COVID-19 Pandemic**

**COVID11 Epidemiology and Registries of COVID-19 and Cancer (including Biorepositories)**

**COVID12 Health Inequities and Disparities during the COVID-19 Pandemic**

**COVID13 Science and Public Policy**

Effects of regional public health policies  
Funding  
Regulatory science and policy  
Workforce  
Other

**RSP Regulatory Science and Policy**

**RSP01 Regulatory Science and Policy**

Biosimilars and generics  
Clinical trial design and accrual  
Combination therapies and codevelopment of investigational agents and diagnostics  
Data science and informatics  
Novel endpoints and biomarkers  
Real-world evidence and retrospective analyses  
Tobacco and e-cigarette regulation  
Other

**SHP Science and Health Policy**

**SHP01 Science and Health Policy**

Cancer health disparities  
Cancer survivorship  
Comparative effectiveness research  
Implementation science  
Patient advocacy and engagement  
Value and cost issues in cancer care  
Other



## AACR MEMBERSHIP: THE ESSENTIAL ASSOCIATION FOR YOU

With over 47,000 members in 127 countries and territories around the world, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to those who conduct cancer research and related biomedical science, both senior and early-career investigators, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR's vision and support our mission to accelerate the prevention and cure of all cancers.

AACR membership categories promote the professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit [AACR.org/International](https://www.aacr.org/International).

## MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than **November 12, 2020**. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than **January 7, 2021**.

## ABSTRACT SPONSORSHIP

### Membership Application Deadlines

November 12, 2020

January 7, 2021

### Abstract Deadlines

November 19, 2020

January 11, 2021  
(Late-Breaking and  
Clinical Trials)

## SCHOLAR AWARDS

### Membership Application Deadline

November 12, 2020

### All Travel Awards Application Deadline

November 19, 2020

Contact the AACR Membership Department with any questions at 215-440-9300 or [membership@aacr.org](mailto:membership@aacr.org).

## AACR MEMBERSHIP CATEGORIES

**Active Membership** is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

**Affiliate Membership** is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

**Associate Membership** is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. **Annual dues are not required.**

**Student Membership** is open to persons who have manifested an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor's degree. Annual dues are not required.

**Sustaining Membership** is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission, purposes, and activities of the Association. Annual dues are determined by the Sustaining Member level.

**Emeritus Membership** is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

**Honorary Membership** is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Please contact the Membership Department at [membership@aacr.org](mailto:membership@aacr.org) or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at [myAACR](http://myAACR) and join us in the global conquest of cancer.

“The knowledge shared by researchers all around the world helped me in understanding the current landscape of cancer research.”



### OPPORTUNITIES TO SUPPORT THE AACR FOUNDATION

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Peter VanPelt, Senior Director, Corporate and Foundation Relations, at 215-446-7256 or via email at [peter.vanpelt@aacr.org](mailto:peter.vanpelt@aacr.org).

### FELLOWS OF THE AACR ACADEMY

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, and collaboration.

The AACR Academy is currently led by Dr. Judy E. Garber and a Steering Committee of ten additional Fellows who serve as a voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.


The next elected class of Fellows of the AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2021 Opening Ceremony.

### AACR SCIENTIFIC ACHIEVEMENT AWARDS, LECTURESHIPS, AND PRIZES

In 1961, the AACR established its first scientific achievement award, partnering with Eli Lilly and Company to present the AACR G.H.A. Clowes Memorial Award. Named for G.H.A. Clowes, a founding member of the AACR and a past research director at Eli Lilly and Company, the award was created to recognize an individual scientist for outstanding recent accomplishments in the field of basic cancer research.

More than fifty years later, the AACR continues to recognize and reward scientific excellence in all areas of cancer research by annually administering 19 different scientific achievement awards and lectureships. In addition to these awards, the AACR annually presents the AACR June L. Biedler Prize for Cancer Journalism, which since 2015 has recognized outstanding journalistic coverage that enhances the general public's understanding of cancer science and medicine.

All 2020-2021 AACR awardees will be formally recognized throughout the AACR Annual Meeting 2021, with the majority of individuals presenting featured scientific lectures highlighting their research accomplishments. We encourage you to attend these lectures and also to nominate your colleagues for one or more of these prestigious awards at [AACR.org/Awards](https://www.aacr.org/Awards).




## **VIRTUAL SATELLITE EDUCATIONAL SYMPOSIA**

Virtual Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information will be available at **[AACR.org/AACR2021](https://aacr.org/AACR2021)**.

## **VIRTUAL EXHIBIT SHOW**

The 2021 AACR Virtual Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at [exhibits@aacr.org](mailto:exhibits@aacr.org).

**“Exceptional during this unexpected hard time.”**  
**AACR VIRTUAL ANNUAL MEETINGS I AND II**  
**2020**



**AACR ANNUAL MEETING 2021**  
**COMMITTEES**



**AACR ANNUAL MEETING  
PROGRAM COMMITTEE**

**Chair**

Charles Swanton

**Vice Chairs**

Lewis C. Cantley  
Heather R. Christofk  
Melissa B. Davis  
Keith T. Flaherty  
Ricky W. Johnstone  
Karen E. Knudsen  
Quynh-Thu Le  
Jean-Charles Soria  
Louis M. Staudt  
David A. Tuveson

**Cochairs**

Peter C. Adamson  
Carole L. Baas  
Dafna Bar-Sagi  
David L. Bartlett  
Julie R. Brahmer  
Javier Cortés  
Riccardo Dalla-Favera  
Luis A. Diaz  
John F. DiPersio  
Steven M. Dubinett  
Tariq Enver  
Douglas T. Fearon  
Irene M. Ghobrial  
Anna R. Giuliano  
W. Nicholas Haining  
James R. Heath  
Manuel Hidalgo  
Melissa M. Hudson  
Stephen D. Hursting  
Christine A. Iacobuzio-Donahue  
Roger S. Lo  
Elli Papaemmanuil  
David Pellman  
Erik Sahai  
Stephen P. Schoenberger  
Shelley S. Tworoger  
Roel Verhaak  
Jane E. Visvader

**AACR EDUCATION COMMITTEE**

**Chair**

Roger S. Lo

*Additional Appointments Pending*

**AACR CLINICAL TRIALS  
COMMITTEE**

**Cochairs**

Julie R. Brahmer  
Manuel Hidalgo

**Members**

Stephen B. Baylin  
Joseph N. Contessa  
Johann S. de Bono  
Stephan A. Grupp  
Susan Halabi  
Matthew D. Hellmann  
Corey J. Langer  
Malcolm J. Moore  
Kunle Odunsi  
Pamela S. Ohashi  
Suresh S. Ramalingam  
Russell J. Schilder  
Yu Shyr  
Mark A. Socinski  
Roger Stupp  
Weijing Sun  
Charles Swanton  
Dan Theodorescu  
Brian Andrew Van Tine  
Ignacio I. Wistuba  
Stephen Yip

*Additional Appointments Pending*